Search results
May 18, 2023 · brought to life for patients. KURA REPORTS POSITIVE PRELIMINARY ZIFTOMENIB COMBINATION DATA IN ACUTE MYELOID LEUKEMIA.
KO-2806 is a potent next-generation FTI designed to improve upon potency, pharmacokinetic and physicochemical properties of earlier FTI drug candidates and address large oncology indications of high unmet need through rational combinations.
Sep 22, 2022 · About Us | Kura Oncology. We aim to help patients with cancer achieve long-lasting remission through targeted, well-tolerated treatments. Built into our pipeline of novel precision medicines is a focus on expanding patient populations and leveraging smart treatment combinations to prevent tumors from developing resistance.
Jun 7, 2024 · We are a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Our pipeline consists of small-molecule product candidates that target cancer signaling pathways, and we intend to pair them with molecular or cellular diagnostics to identify those patients most likely to ...
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target...
Apr 22, 2024 · SAN DIEGO, April 22, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that its investigational drug, ziftomenib, has been granted Breakthrough Therapy Designation (BTD) by the U.S. Food ...
Dec 20, 2023 · Kura Oncology’s clinical trial programs represent the next step toward our goal of realizing the full potential of precision medicine. Our investigational trials are studying innovative therapeutic candidates with the potential to help patients with certain cancers lead better, longer lives.
At Kura, we are leading the next era of precision medicine — an era that delivers on the critical need to anticipate and circumvent common mechanisms of treatment resistance and extends the past decade of success in targeted medicines to broader patient populations.
Apr 22, 2024 · Kura Oncology, Inc. – Ziftomenib is the first investigational treatment to be granted Breakthrough Therapy Designation for NPM1-mutant AML –. – Registration-directed trial of ziftomenib in...
Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Our small-molecule drug candidates target ...
